JOSE ANTONIO
GIRON GONZALEZ
Catedrático de Universidad
José A.
Mira-Escarti
Publicaciones en las que colabora con José A. Mira-Escarti (16)
2015
-
Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 34, Núm. 9, pp. 1879-1884
2013
-
Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis
Clinical Infectious Diseases, Vol. 56, Núm. 11, pp. 1646-1653
-
Short communication: Atazanavir-based therapy is associated with higher hepatitis C viral load in HIV type 1-infected subjects with untreated hepatitis C
AIDS Research and Human Retroviruses, Vol. 29, Núm. 2, pp. 223-225
2012
-
Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients
AIDS, Vol. 26, Núm. 13, pp. 1721-1724
-
Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis
Clinical Infectious Diseases, Vol. 55, Núm. 12, pp. 1719-1726
2009
-
Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus
Hepatology, Vol. 50, Núm. 4, pp. 1056-1063
2008
-
Baseline serum low-density lipoprotein cholesterol levels predict response to hepatitis C virus therapy in HIV/hepatitis C virus coinfected patients
AIDS, Vol. 22, Núm. 8, pp. 923-930
-
Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen
Journal of Antimicrobial Chemotherapy, Vol. 62, Núm. 4, pp. 793-796
-
Liver toxicity of antiretroviral combinations including atazanavir/ ritonavir in patients co-infected with HIV and hepatitis viruses: Impact of pre-existing liver fibrosis
Journal of Antimicrobial Chemotherapy, Vol. 61, Núm. 4, pp. 925-932
2007
-
Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients
Journal of Antimicrobial Chemotherapy, Vol. 60, Núm. 6, pp. 1347-1354
-
Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients
Antiviral Therapy, Vol. 12, Núm. 8, pp. 1225-1235
-
Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients
Antiviral Therapy, Vol. 12, Núm. 4, pp. 523-529
2006
-
Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C
Antiviral Therapy, Vol. 11, Núm. 7, pp. 839-846
-
Incidence of and risk factors for severe hepatotoxicity of nelfinavir-containing regimens among HIV-infected patients with chronic hepatitis C
Journal of Antimicrobial Chemotherapy, Vol. 58, Núm. 1, pp. 140-146
-
Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes
Gut, Vol. 55, Núm. 3, pp. 409-414
2002
-
Factors related to the chronicity and evolution of hepatitis C infection in patients co-infected by the human immunodeficiency virus
Clinical Microbiology and Infection, Vol. 8, Núm. 9, pp. 589-597